BioLineRx (BLRX) Research & Development (2013 - 2025)
BioLineRx (BLRX) posted Research & Development of -$2.4 million for Q4 2025, down 41.07% on a QoQ basis from -$1.7 million in Q3 2025, and down 30.03% year-over-year from -$3.5 million in Q4 2024.
BioLineRx (BLRX) has 13 years of Research & Development data on file, last reported at -$2.4 million in Q4 2025.
- In Q4 2025, Research & Development fell 30.03% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$8.1 million (up 11.54% YoY), while the FY2025 annual figure was -$8.1 million, up 11.54% from the prior year.
- Research & Development fell to -$2.4 million in Q4 2025, from -$1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $5.4 million in Q2 2022 and bottomed at -$5.1 million in Q4 2021.
- A 5-year average of -$2.3 million and a median of -$2.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 155.72% — and 2024, when it jumped 39.88%.
- Year by year, Research & Development stood at -$5.1 million in 2021, then soared by 33.09% to -$3.4 million in 2022, then advanced by 9.56% to -$3.1 million in 2023, then jumped by 39.88% to -$1.9 million in 2024, then sank by 30.03% to -$2.4 million in 2025.
- The last three Research & Development figures came in at -$2.4 million (Q4 2025), -$1.7 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.43 Mn |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | -1.87 Mn |
| Sep 30, 2024 | -2.57 Mn |
| Jun 30, 2024 | -2.23 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | -3.10 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | -4.44 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | -4.92 Mn |
| Jun 30, 2021 | 5.14 Mn |
| Mar 31, 2021 | -4.28 Mn |
| Dec 31, 2020 | -4.63 Mn |
| Sep 30, 2020 | -3.48 Mn |
| Jun 30, 2020 | 4.64 Mn |
| Mar 31, 2020 | -5.42 Mn |
| Dec 31, 2019 | -8.19 Mn |
| Sep 30, 2019 | -5.56 Mn |
| Jun 30, 2019 | 5.30 Mn |
| Mar 31, 2019 | -4.39 Mn |
| Dec 31, 2018 | -5.23 Mn |
| Sep 30, 2018 | -5.03 Mn |
| Jun 30, 2018 | 4.48 Mn |
| Mar 31, 2018 | -5.07 Mn |
| Dec 31, 2017 | -6.20 Mn |
| Sep 30, 2017 | -5.65 Mn |
| Jun 30, 2017 | 4.06 Mn |
| Mar 31, 2017 | -3.59 Mn |
| Dec 31, 2016 | -2.94 Mn |
| Sep 30, 2016 | -2.95 Mn |
| Jun 30, 2016 | -2.74 Mn |
| Mar 31, 2016 | -2.54 Mn |
| Dec 31, 2015 | -2.81 Mn |
| Sep 30, 2015 | -2.58 Mn |
| Jun 30, 2015 | -2.89 Mn |
| Mar 31, 2015 | -3.21 Mn |
| Dec 31, 2014 | -3.38 Mn |
| Sep 30, 2014 | -2.98 Mn |
| Jun 30, 2014 | -2.79 Mn |
| Mar 31, 2014 | -2.72 Mn |
| Dec 31, 2013 | -978,000.00 |
| Sep 30, 2013 | -2.32 Mn |
| Jun 30, 2013 | -3.34 Mn |
| Mar 31, 2013 | -5.33 Mn |